Dianthus Therapeutics, Inc. (DNTH) stock
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$91.81−0.67 (-0.72%)
Close on Nov 13, 2026Market cap $5.14BP/E –Yield 0.00%
Dianthus Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Dianthus Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$175.15M. For fiscal 2025 it was -$129.06M. The highest annual figure on record is -$6.53M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$129.06M | – |
| FY2024 | Dec 31, 2024 | -$78.18M | – |
| FY2023 | Dec 31, 2023 | -$36.86M | – |
| FY2022 | Dec 31, 2022 | -$29.07M | – |
| FY2021 | Dec 31, 2021 | -$59.53M | – |
| FY2020 | Dec 31, 2020 | -$64.02M | – |
| FY2019 | Dec 31, 2019 | -$57.10M | – |
| FY2018 | Dec 31, 2018 | -$41.89M | – |
| FY2017 | Dec 31, 2017 | -$22.26M | – |
| FY2016 | Dec 31, 2016 | -$6.53M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$50.33M | – |
| Q2 FY2026 | Jun 30, 2026 | -$48.98M | – |
| Q1 FY2026 | Mar 31, 2026 | -$28.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.89M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.85M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.99M | -161.0% |
| Q2 FY2023 | Jun 30, 2023 | -$4.73M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.85M | – |
| Q3 FY2022 | Sep 30, 2022 | $16.38M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.69M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.43M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.66M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.63M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.51M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.03M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.94M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.55M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.60M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.23M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.44M | – |
See a number that looks wrong?